Fig. 3.

Functional interrogation of single CRISPR/Cas9-edited hematopoietic stem cells in NSG mice. a Percentage of CRISPR/Cas9 edited LT-HSCs injected NSG mice with engraftment (>5% based on human CD45⁺ expression in RF) and high CRISPR/Cas9 knockout efficiency (>90% based on PCR and Sanger sequencing) from each of three cohorts (n = 3 animal cohorts with independent cord blood pools). b Engraftment levels of control and GATA1-short edited LT-HSCs injected NSG mice based on human CD45⁺ expression in RF and BM. c Percentage of CD41⁺CD45⁻ megakaryocytes of control and GATA1-Short edited LT-HSCs injected NSG mice in RF and BM (unpaired t test P < 0.005 for RF GATA1-Short versus RF control and unpaired t test P = 0.107 for BM GATA1-Short versus BM control). d Percentage of CD19⁺CD45⁺ lymphoid cells in control and GATA1-Short edited LT-HSCs injected NSG mice in RF and BM (unpaired t test P < 0.005 for RF GATA1-Short versus RF control). e Absolute cell numbers of different lineages in control and GATA1-Short edited LT-HSCs injected NSG mice in RF and BM (unpaired t test P < 0.01 for B-lymphoid RF GATA1-Short versus RF control and unpaired t test P < 0.005 for megakaryocytes RF GATA1-Short versus RF control). f Representative flow cytometry plots of control and GATA1-Short edited LT-HSCs injected NSG mice in RF showing CD41⁺CD45⁻ megakaryocytes and GlyA⁺CD45⁻ erythroid cells. Error bars represent standard deviations